PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit
PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014
PDL BioPharma to Participate in Upcoming Investor Conferences
PDL BioPharma Completes Regular Quarterly Dividend Payment
PDL BioPharma Provides Second Quarter 2014 Revenue Guidance of $140 Million